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A B S T R A C T
Objectives: Dengue represents the most important arboviral infection worldwide. Onset of circulatory
collapse can be unpredictable. Biomarkers that can identify individuals at risk of plasma leakage may
facilitate better triage and clinical management.
Design: Using a nested case-control design, we randomly selected subjects from a prospective cohort
study of dengue in Colombia (n = 1582). Using serum collected within 96 hours of fever onset, we tested
19 biomarkers by ELISA in cases (developed dengue hemorrhagic fever or dengue shock syndrome (DHF/
DSS); n = 46), and controls (uncomplicated dengue fever (DF); n = 65) and healthy controls (HC); n = 15.
Results: Ang-1 levels were lower and angptl3, sKDR, sEng, sICAM-1, CRP, CXCL10/IP-10, IL-18 binding
protein, CHI3L1, C5a and Factor D levels were increased in dengue compared to HC. sICAM-1, sEng and
CXCL10/IP-10 were further elevated in subjects who subsequently developed DHF/DSS (p = 0.008,
p = 0.028 and p = 0.025, respectively). In a logistic regression model, age (odds ratio (OR) (95% CI): 0.95
(0.92-0.98), p = 0.001), hyperesthesia/hyperalgesia (OR; 3.8 (1.4-10.4), p = 0.008) and elevated sICAM-1
(>298ng/mL: OR; 6.3 (1.5-25.7), p = 0.011) at presentation were independently associated with
progression to DHF/DSS.
Conclusions: These results suggest that inﬂammation and endothelial activation are important pathways
in the pathogenesis of dengue and sICAM-1 levels may identify individuals at risk of plasma leakage.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
Contents lists available at ScienceDirect
International Journal of Infectious Diseases
jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Background
Dengue is an emerging infectious disease of global importance
with 2.5 to almost 4 billion people residing in dengue endemic
countries in which an estimated 50-100 million infections occur
annually.1,2 Historically, the highest risk areas for dengue fever
were in Southeast Asia and the western Paciﬁc (where* Corresponding author. Sandra Rotman Laboratories, Sandra Rotman Centre for
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WCLiles@medicine.washington.edu (W.C. Liles), luisangelvillarc@gmail.com
(L.A. Villar-Centeno), kevin.kain@uhn.ca (K.C. Kain).
http://dx.doi.org/10.1016/j.ijid.2015.07.027
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).approximately 75% of the global disease burden is located).
However, the risk of dengue, and severe dengue, is increasing in
the Americas following disease re-emergence after lapsed vector
control programs.3 Between 2000 and 2006, the majority of cases
reported (68%) were registered in this region.4 Cyclical outbreaks
of dengue in the Caribbean, and Central and South America have
resulted in considerable morbidity and mortality. In 2013,
2.35 million cases of dengue were reported in the Americas, of
which 37,687 cases were classiﬁed as severe dengue, with Brazil
and Colombia recording the highest incidence.
Dengue is an important consideration in the differential
diagnosis of fever in endemic countries and in travelers returning
from these regions.5 Dengue infection presents with a wide
spectrum of signs and symptoms, including rapid onset of fever
that may be accompanied by myalgia, arthralgia, retro-orbital
pain, facial ﬂushing, erythema, nausea, vomiting, cutaneousciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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as evidenced by a positive tourniquet test. A small percentage of
individuals with dengue will develop life-threatening complica-
tions, which can include plasma leak and circulatory collapse. The
clinical evolution of disease can be unpredictable making the
initial clinical assessment a critical step in patient management.6
Dengue is a single-stranded RNA virus with four distinct
serotypes (DEN-1 to -4). Risk of haemorrhage and plasma leak is
generally higher in secondary infections, but other factors
including age, sex, and other host and viral determinants also
contribute to disease susceptibility. The prevailing hypothesis is
that cross-reactive, non-neutralizing antibodies in secondary
heterotypic infections facilitate viral entry into target cells, thereby
increasing viral load, enhancing deleterious inﬂammatory
responses and contributing to endothelial activation and dysfunc-
tion (reviewed in7). The endothelium is central to dengue
pathogenesis as increased vascular permeability and fragility are
deﬁning features in severe disease. However, inﬂammation,
coagulation and complement activation are also involved in
disease pathogenesis, and alterations in soluble mediators from
these pathways have been described in severe dengue infections.8–
18
Clinical management of dengue depends on appropriate triage,
referral and treatment of cases, especially in outbreaks. Although
there are no speciﬁc anti-infective or immunomodulatory thera-
pies to prevent plasma leak, appropriate ﬂuid management and
supportive care can reduce the mortality rate from over 20% to less
than 1%.3,19 With rates of severe disease on the rise, especially in
the Americas,20–22 new tools are urgently needed to improve
patient triage and risk prediction of severe disease.23 We
investigated whether host biomarkers, chosen from pathways
implicated in dengue pathogenesis, were altered in dengue relative
to healthy controls, and whether the biomarkers assessed during
the acute phase of disease were associated with the subsequent




All four dengue virus serotypes circulate in Colombia, which
reports the highest number of severe dengue cases and deaths in
the region.3,24 Bucaramanga is a metropolitan area in northeastern
Colombia where the incidence of dengue ranges from 113-269
cases per 100,000 people.25–27 Participants from Bucaramanga
who presented within 96 hours of fever onset were eligible for
recruitment if they were greater than ﬁve years of age. Subjects
were excluded based on the presence of the following conditions:
history of concomitant diseases such as diabetes, acquired
immunodeﬁciency syndrome (AIDS), hematologic disorders, can-
cer, or cardiac disease, albuminemia (<3 g/dL), evidence of severe
dengue at presentation, for example major bleeding, effusions, or
shock. After participants provided informed consent, a physical
examination was performed, and a blood sample was obtained to
determine hematocrit, albumin levels, and platelet and leukocyte
counts. A serum sample was collected and stored at -80C for future
biomarker assessment.
Diagnosis of dengue virus infection was conﬁrmed based on
viral isolation or serology (seroconversion from a negative to a
positive IgM test or a four-fold increase in dengue antibodies in a
convalescent blood sample). All study participants were enrolled
before the development of DHF/DSS. Participants were followed
daily until day 7 of disease with daily microhematocrit measure-
ments to facilitate the recognition of severe dengue. Platelet counts
were repeated daily for subjects with previous platelet counts lessthan 120,000/mm3 or if there were signs of spontaneous
haemorrhage, effusion, oedema or change in hematocrit > 10%.
Study participants were classiﬁed as DF or DHF/DSS following
recovery and full chart review using the 1997 WHO classiﬁcation
system according to the study design.28
2.2. Study Design
This study was a case-control study nested within the
prospective cohort study (n = 1582) of suspected dengue in
Bucaramanga, Colombia. Blood samples were collected from study
participants at clinical presentation. Cases were individuals who
developed DHF/DSS and controls had dengue fever (DF). Study
subjects with available serum samples were eligible for biomarker
testing and were randomly chosen from the cohort database using
computer generated simple randomization. Serum samples were
collected from 15 healthy Bucaramangan adults to derive a
population-based normal range.
2.3. Biomarker Assessment
Serum concentrations of biomarkers were measured in samples
collected at presentation using ELISA DuoSets from R&D Systems
(Minneapolis, MN). Biomarkers measured were C-reactive protein
(CRP), CXCL10/IP-10, IL-18 binding protein (IL-18BP), IL-10,
chitinase 3-like 1 (CHI3L1), C5a, complement factor D, angiopoie-
tin-1 (Ang-1), angiopoietin-2 (Ang-2), soluble Tie-1 (sTie-1),
soluble Tie-2 (sTie-2), angiopoietin-like protein 3 (Angptl3),
angiopoietin-like protein 4 (Angptl4), vascular endothelial growth
factor (VEGF), soluble VEGF R1 (sFlt-1), soluble VEGF R2 (sKDR),
soluble endoglin (sEng), soluble intercellular adhesion molecule-1
(sICAM-1) and platelet factor 4. All ELISAs were validated prior to
use, and sample dilutions were optimized for each biomarker using
a dilution curve of serum obtained from febrile subjects with
dengue fever in Bucaramanga. ELISAs were tested according to the
manufacturer’s instructions (R&D Systems) with minor modiﬁca-
tions previously described.29
2.4. Statistical Analysis
GraphPad Prism v5, SPSS v20 and MedCalc1 v12 were used for
statistical analysis. Comparisons of continuous variables were
performed using the Mann-Whitney U test. Comparisons of
proportions were performed using Pearson chi-square test or
Fisher’s exact test, as appropriate. Exploratory logisitic regression
models were built using forward step-wise selection including all
variables with p < 0.10 by bivariate analysis. Model ﬁt was
assessed using the Hosmer-Lemeshow test and ensuring the term
was not signiﬁcant p > 0.05. Biomarkers were dichotomized by
generating a ROC curve and using the Youden index to identify the
optimal cut-off (Youden index: J = max [sensitivity+speciﬁcity]-1).
3. Results
3.1. Clinical Characteristics of Subjects that Developed DHF/DSS
111 subjects with microbiologically conﬁrmed dengue virus
infection were included in the current study along with 15 healthy
controls from Bucaramanga. 65 had DF while 46 developed DHF/
DSS over the course of clinical follow up.3 Individuals that
developed DHF/DSS were signiﬁcantly younger, had higher axillary
temperatures and lower mean arterial pressure at presentation
and were more likely to report chills, hyperesthesia/hyperalgesia,
and dizziness than those with DF (Table 1). The median day
of illness at presentation was day 4 for both groups (p = 0.461,
Table 1
Demographic and clinical features of cohort at presentation
DF (n = 65) DHF/DSS (n = 46) P value
Demographics
Age, years 28.0 (19.0-45.5) 21.0 (14.0-31.3) 0.006
Sex (% F) 35 (53.8) 25 (54.3) 0.958
Height, cm 163 (155-172) 160 (150-168) 0.094
Weight, kg 63.0 (54.0-76.5) 59.0 (47.0-70.0) 0.156
Duration of fever, hours 77.0 (66.8-89.0) 75.3 (60.1-88.8) 0.733
Laboratory
Axillary temperature, 8C 36.3 (36.0-37.0) 36.8 (35.9-37.9) 0.067
Platelet count (x103ml/mL) 126.0 (83.0-182.0) 119.5 (79.8-176.3) 0.940
Leukocyte count 2900 (2100-4000) 2950 (2275-3925) 0.682
Hematocrit 39.4 (36.1-42.6) 38.0 (35.5-42.0) 0.436
Mean arterial pressure 88.0 (80.7-94.0) 83.7 (76.7-90.8) 0.038
Tourniquet test (# petechiae) 22.0 (4.5-32.5) 17.5 (5.0-25.0) 0.281
Aspartate aminotransferase a 59.9 (40.0-114.8) 56.5 (43.0-95.0) 0.958
Alanine aminotransferase a 37.6 (22.0-57.0) 30.7 (24.0-74.0) 0.889
Lactate dehydrogenase b 320.0 (200.5-433.1) 333.8 (172.0-716.9) 0.540
Albumin c 4.5 (4.2-4.7) 4.1 (3.8-4.5) 0.069
Creatinine phosphokinase c 134.6 (59.8-769.0) 76.6 (54.1-184.5) 0.170
Cholesterol d 155.1 (141.0-164.0) 148.6 (113.3-154.6) 0.118
Trigylcerides d 121.7 (87.2-175.2) 159.1 (72.7-203.3) 1.000
Signs and Symptoms (%)
Headache 61 (93.8) 44 (95.7) 0.678
Retro-orbital pain 43 (66.2) 35 (76.1) 0.259
Asthenia 46 (70.8) 31 (67.4) 0.704
Muscle Pain 59 (90.8) 41 (91.1), n = 45 0.951
Joint Pain 52 (80.0) 36 (80.0), n = 45 1.000
Chills 64 (98.5) 41 (89.1) 0.032
Sore throat 23 (35.4) 12 (28.3) 0.430
Facial erythema 35 (53.8) 22 (47.8) 0.532
Rash 25 (38.5) 23 (53.5), n = 43 0.124
Hyperesthesia/hyperalgesia 15 (23.1) 17 (40.5) 0.055
Nausea 47 (72.3) 38 (82.6) 0.207
Vomiting 20 (30.8) 18 (39.1) 0.360
Diarrhea 25 (38.5) 16 (34.8) 0.692
Abdominal pain 31 (48.4) 30 (65.2) 0.081
Blurred vision 24 (36.9) 20 (44.4) 0.429
Dizziness 39 (60.0) 35 (77.8) 0.051
Conjunctival injection 31 (47.7) 17 (37.0) 0.261
Orthostatic hypotension 8 (12.3) 9 (19.6) 0.296
Participants with dengue fever (DF) that did not develop complications, DF participants that developed DHF/DSS.
a DF (n = 40), DHF/DSS (n = 31); b DF (n = 38), DHF/DSS (n = 31); c DF (n = 24), DHF/DSS (n = 18), d DF (n = 15), SD (n = 13).
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after presentation.
3.2. Alterations of Host Biomarkers in Dengue
We evaluated 19 host biomarkers in patients with dengue virus
infection and compared them to healthy controls to determine
which markers were elevated during the acute febrile phase of
dengue (2-4 days after symptom onset). Biomarkers were broadly
chosen from four pathways implicated in dengue pathogenesis:
inﬂammation, endothelial activation, complement activation, and
coagulation. Eleven biomarkers differed in dengue infection
compared to healthy controls (p < 0.05 by Mann-Whitney U test,
Table 2). Ang-1 was signiﬁcantly reduced while Angptl3, sKDR,
sEng, sICAM-1, CRP, CXCL10 (IP-10), IL-18 binding protein, CHI3L1,
C5a and Factor D were increased in dengue fever compared to
healthy controls (Figure 1).
3.3. Host Biomarkers are Associated with the Development of
Hemorrhage
We hypothesized that host biomarkers altered in dengue
precede clinical manifestations of hemorrhage and vascular leak.
Three biomarkers were signiﬁcantly elevated at presentation in
subjects that subsequently developed DHF/DSS compared to those
with an uncomplicated disease course: sICAM-1, sEng and CXCL10
(p = 0.008, p = 0.028 and p = 0.025 respectively) (Table 2, Figure 2).Levels of CXCL10 were signiﬁcantly correlated with sICAM-1 levels
(Spearman’s rho, p-value; 0.468, p < 0.001) and sEng levels (0.348,
p < 0.0001), but there was no statistically signiﬁcant association
between sEng and sICAM-1 (0.184, p = 0.053).
We explored the relationship between the biomarkers associ-
ated with disease progression and routine clinical laboratory
values at the time of clinical presentation, including platelet and
leukocyte counts, hematocrit, bleeding tendency, mean arterial
pressure and liver enzymes. Levels of sICAM-1 and sEng correlated
weakly and negatively with the platelet count (Spearman’s rho, p-
value: sICAM-1, -0.197, p = 0.038; sEng, -0.219, p = 0.021). CXCL10
correlated with both platelet and leukocyte counts (platelet count,
-0.533, p < 0.0001; leukocyte count, -0.355, p < 0.0001). Biomark-
er levels were not correlated with hematocrit, the number of
petechiae by tourniquet test or mean arterial pressure. Both
sICAM-1 and CXCL10 were signiﬁcantly correlated with AST and
ALT (AST: sICAM-1, 0.375, p = 0.001; CXCL10, 0.314, p = 0.008; ALT:
sICAM-1, 0.410, p < 0.0001; CXCL10, 0.287, p = 0.015). sEng did not
correlate with AST or ALT but was negatively correlated with total
cholesterol and low density lipoproteins (cholesterol, -0.465,
p = 0.013; low density lipoprotein, -0.601, p = 0.001).
3.4. Predictive Models of DHF: Integrating Clinical and Biomarker
Data
Based on the hypothesis that host biomarkers can add value to
clinical ﬁndings, we explored models to integrate our biomarker
Table 2
Biomarkers in Dengue
HC (n = 15) Dengue
DF (n = 65) DHF/DSS (n = 46)
Inﬂammation
CRP a 1.8 (2.3-6.1)*** 18.7 (9.2-41.3) 21.0 (6.4-41.4)
IP-10 0.2 (0.2-0.4) *** 2.8 (1.0-4.4) 3.6 (1.8-5.0) y
IL-18 BP 5.8 (4.3-8.3) *** 62.3 (36.4-97.0) 75.9 (52.8-90.6)
IL-10 b 0.03 (0.02-0.2) 145.2 (19.5-390.9) 58.0 (19.5-357.9)
CHI3L1 44.5 (35.8-61.3)* 61.6 (44.6-81.2) 57.3 (40.3-78.3)
Complement System
C5a 18.5 (13.8-22.1) *** 53.8 (33.9-62.8) 52.5 (35.3-67.4)
Factor D a 1.1 (1.0-1.3)** 1.4 (1.1-1.6) 1.3 (1.2-1.6)
Endothelium
Ang-1 44.9 (33.0-53.6)* 32.2 (25.6-43.9) 31.6 (22.3-47.0)
Ang-2 1.4 (1.0-2.6) 1.7 (1.3-2.4) 2.1 (1.3-2.9)
sTie-1 8.3 (6.8-12.7) 10.5 (8.1-12.9) 9.6 (8.1-13.5)
sTie-2 8.7 (6.4-9.7) 7.3 (5.5-8.9) 8.1 (6.0-9.9)
Angptl3 108.4 (82.3-117.5) *** 164.0 (140.6-192.9) 170.8 (146.5-196.3)
Angptl4 44.7 (30.2-90.9) 37.8 (29.3-56.3) 41.7 (33.6-64.2)
VEGF b 0.2 (0.2-0.3) 128.2 (48.8-291.9) 124.3 (48.8-321.5)
sFlt-1 b 39.1 (39.1-343.5) 39.1 (39.1-863.3) 94.6 (39.1-1074)
sKDR 5.3 (4.5-6.0) * 6.1 (5.5-7.1) 6.1 (5.5-7.1)
sEng 6.6 (5.7-8.4) *** 11.0 (9.2-13.2) 12.8 (10.3-14.7) y
sICAM-1 169.3 (135.8-287.3) *** 329.1 (284.1-467.1) 399.9 (323.0-539.0) yy
Coagulation
Platelet factor 4 a 18.5 (15.6-27.1) 25.7 (16.2-41.2) 23.8 (15.6-37.7)
Healthy controls (HC), Participants with dengue that did not develop complications (DF), participants with dengue that developed DHF/DSS (DHF/DSS).
Biomarker concentration in ng/mL unless otherwise indicated, a mg/mL, b pg/mL.
*** p < 0.001 (HC vs. all dengue), ** p < 0.01 (HC vs. all dengue), * p < 0.05 (HC vs. all dengue).
yy p < 0.01 (DF vs. DHF/DSS), y p < 0.05 (DF vs. DHF/DSS).
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bivariate analysis (Table 1) were considered for the predictive
models and biomarkers were included as dichotomous variables
with the following cut-offs (CXCL10 >1.07ng/m; sEng >11.8 ng/
mL; sICAM-1 >298.2 ng/mL).
Using forward step-wise logistic regression, we developed a
clinical model consisting of age and hyperesthesia/hyperalgesia
(Table 3). We then added the biomarkers into the clinical model to
generate a biomarker model that included age, hyperesthesia/
hyperalgesia and sICAM-1. In the biomarker model, age was
associated with a 0.95 (95% CI, 0.92-0.98, p = 0.002) odds of DHF/
DSS while the presence of hyperesthesia/hyperalgesia was
associated with 3.8-fold increased odds of developing DHF/DSS
(95% CI, 1.4-10.4, p = 0.008). sICAM-1 >298.2 ng/mL was associat-
ed with a 6.3-fold increased odds of developing DHF/DSS (95% CI,
1.5-25.7, p = 0.011) (Table 3).
4. Discussion
Dengue fever is an emerging infectious disease endemic to the
tropics and sub-tropics that causes cyclical outbreaks or epidemics
that can overwhelm health care resources. Only a small proportion
of infections will progress to severe disease (DHF/DSS), but it is
difﬁcult to accurately identify individuals at risk of plasma leak and
circulatory collapse during the acute phase of disease when
individuals are likely to ﬁrst seek medical care. In this study, we
investigated whether host proteins derived from pathways
implicated in the pathogenesis of dengue would differentiate
between subjects with an uncomplicated disease course versus
those that developed DHF/DSS. Compared to healthy controls,
eleven proteins were altered in dengue infection (ang-1, angptl3,
sKDR, sEng, sICAM-1, CRP, CXCL10/IP-10, IL-18BP, CHI3L1, C5a,
Factor D), and three proteins were signiﬁcantly elevated at
presentation in individuals who subsequently developed DHF/
DSS (sEng, sICAM-1 and CXCL10). sICAM-1 was an independent
predictor of DHF/DSS (Figure 2, Table 3). These results suggest that
host biomarkers, once validated, may have clinical utility in patienttriage and risk-stratiﬁcation for referral, admission and imple-
mentation of timely supportive measures.
Consistent with other studies, levels of sICAM-1, CRP, CXCL10,
C5a and Factor D were elevated and levels of Ang-1 were reduced
in subjects with dengue.11,12,16,30–36 IL-10 was neither elevated in
dengue nor was it associated with the development of DHF/DSS in
this population unlike ﬁndings reported from Venezuela;37,38 but
consistent with a recent study from Sri Lanka.39 There were no
differences in levels of VEGF or its receptors in predicting DHF/DSS,
unlike a report from Thailand.40 These discrepancies may reﬂect
age differences;41 however, other factors (host and viral genotype
or the kinetics of infection) may also be involved.
This study identiﬁed four novel biomarkers associated with
dengue infection: CHI3L1, IL-18 BP, Angptl3, and sEng. CHI3L1 is
expressed by a variety of cells and tissues (including leukocytes
and endothelium) in response to inﬂammatory stimuli and is
involved in modulating inﬂammatory responses (reviewed in42).
Elevated levels of CHI3L1 have been associated with dysregulated
inﬂammatory responses in other infections such as pneumonia and
malaria.43–45 IL-18BP binds and neutralizes IL-18, a pro-inﬂam-
matory cytokine that is induced by and further induces expression
of IFN-g. IL-18 has been implicated in resistance to dengue
infection in a murine model,46 but IL-18 has also been associated
with dengue disease severity in humans.17 Angptl3 is a protein
expressed by the liver and is involved in regulating angiogenesis
and lipid metabolism;47–49 however, Angptl3 levels were not
associated with levels of cholesterol (total, HDL or LDL) triglyc-
erides or liver enzymes AST or ALT in this study.
Endoglin (Eng) is an integral membrane protein that serves as a
co-receptor for protein members of the transforming growth factor
(TGF)-ß family. It is predominantly expressed on endothelium and
is highly expressed at sites of active angiogenesis (including
inﬂammation and vascular injury).50,51 sEng is generated through
proteolytic processing of membrane bound Eng through matrix
metalloproteinase-1452 and regulates vascular tone and perme-
ability in addition to modulating immune responses.53 Over-
expression of sFlt-1 and sEng leads to increased microvascular
Figure 1. Host biomarkers that are altered in dengue infection.
(A-K) Box and whisker plots showing the distribution of biomarkers signiﬁcantly different (p < 0.05) in healthy controls from Bucaramanga (n = 15) compared to subjects
with serological conﬁrmation of dengue fever (n = 111). Boxes show the median and interquartile range while the whiskers denote the minimum/maximum greatest value
excluding outliers (deﬁned as values 1.5x greater than the 3rd quartile or 1.5x less than the 1st quartile). The mean is denoted by the plus-sign (+). Data were analysed using the
Mann-Whitney U test.
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Figure 2. Biomarkers associated with the development of DHF/DSS.
Median and scatter of serum biomarkers (sICAM-1, sEng, CXCL10) measured at presentation in dengue infection in participants with uncomplicated dengue fever (DF, n = 65)
and those who developed DHF/DSS (n = 46). Data were analysed using Mann-Whitney U test.
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microvascular permeability in an organ speciﬁc manner.53
Elevated sEng levels have been reported in a number of infectious
and non-infectious conditions associated with vascular dysfunc-
tion including malaria and preeclampsia.53–57 In this study, sEng
levels were higher in individuals that subsequently developed
DHF/DSS compared to those with DF. These ﬁndings are consistent
with reports of sEng as a vascular permeability factor, but conﬂict
with a recent study that found no difference in circulating sEng
levels in dengue patients with plasma leakage assessed by X-ray or
ultrasound on admission.58 It is also possible that sEng may be
modulating inﬂammatory responses through its effects on TGF-b
signalling.
CXCL10 is an IFN-g induced proinﬂammatory chemokine that is
highly expressed by primary cells infected with dengue vi-
rus34,59,60 and by primary cells from dengue-infected patients.61
CXCL10 promotes viral clearance by binding to heparin sulfate, a
co-receptor for viral entry,62,63 and peak levels of CXCL10 have
been temporally associated with maximal virus production from
mononuclear cells.64 In murine models, CXCL10 is associated with
resistance to dengue infection.63,65 CXCL10 levels are elevated
during the acute febrile phase of infection34,35,66 and are higher in
dengue than other febrile illnesses.33,34 There are little human data
on CXCL10 levels and disease severity. A report from Colombia
noted increased expression of CXCL10 in the cardiac tissue of a
fatal case of dengue haemorrhagic fever,67 but this ﬁnding requires
validation. In this study, CXCL10 levels were higher in individuals
that developed DHF/DSS. It is possible that CXCL10 was
upregulated as an anti-viral response and individuals that
developed DHF/DSS had higher viral loads, consistent with other
reports.68–70 Further studies are required to determine whether
CXCL10 in humans is associated with resistance by reducing viral
load or whether it may exacerbate disease by amplifying
proinﬂammatory responses.Table 3
Clinical and Biomarker Logistic Regression Models to Predict DHF/DSS
B (S.E.) Wald 
CLINICAL
Age -0.047 (0.015) 9.397
Hyperesthesia/hyperalgesia 1.184 (0.480) 6.088
Constant 0.471 (0.432) 1.185
BIOMARKER
Age -.052 (0.016) 10.733
Hyperesthesia/hyperalgesia 1.345 (0.511) 6.933
sICAM-1 (>298.2ng/mL) 1.837 (0.719) 6.523
Constant -0.998 (0.748) 1.782
Coefﬁcient, B; standard error, (S.E.); degrees of freedom, Df; odds ratio, OR: conﬁdence
CLINICAL: Hosmer-Lemeshow (Chi-square, 12.506; df, 7; p = 0.085), -2 Log Likelihood (
BIOMARKER: Hosmer-Lemeshow (Chi-square, 11.008; df, 8; p = 0.201), -2 Log LikelihooICAM-1, a member of the immunoglobulin superfamily, exists
as both a transmembrane (ICAM-1) and a soluble protein (sICAM-
1). ICAM-1 is expressed on a variety of cells including leukocytes,
hepatocytes and endothelial cells and is upregulated by inﬂam-
matory stimuli. Increased expression of ICAM-1 has been reported
in dengue fever on endothelium18,71–74 and leukocytes.75,76
Upregulation of endothelial ICAM-1 occurs upon stimulation with
sera from dengue patients, supernatants from dengue-infected
cells or via direct stimulation with virus antigen in vitro.
Stimulation occurs, at least in part, in a TNF and NF-kB-dependent
manner.18,71–73 Elevated sICAM-1 levels have been reported in
dengue fever but have not been previously associated with disease
severity,30,31,75,77 except in a study by Bethell et al., where sICAM-1
was decreased in Vietnamese children with dengue shock
syndrome. In the latter study, the decrease was attributed to a loss
of protein secondary to capillary leak that occurs in severe dengue.78
In this study, sICAM-1 levels were increased in individuals with
dengue infection compared to healthy controls (Figure 1), and
sICAM-1 levels were higher in individuals that subsequently
developed DHF/DSS compared to individuals with an uncompli-
cated course of DF (Figure 2). This effect was most pronounced
when samples were collected prior to defervescence. sICAM-1
levels were positively correlated with liver enzymes AST and ALT
and negatively correlated with platelet counts. Decreased platelet
counts and increases in AST have been associated with severe
disease onset in dengue fever,79,80 but were not predictive in this
nested case-control study, which may reﬂect a lack of power.
sICAM-1 was an independent predictor of DHF/DSS in a clinical
model alongside age and hyperesthesia/hyperalgesia and im-
proved clinical prediction. These ﬁndings suggest that early
systemic inﬂammation in dengue may lead to upregulation of
cell-bound ICAM-1 and trigger cleavage of sICAM-1. The kinetics
and functional consequences of elevated sICAM-1 in dengue
infection require further investigation.Df P Value OR (95% CI)
 1 .002 0.95 (0.93-0.98)
 1 .014 3.3 (1.3-8.4)
 1 .276 1.6
 1 .001 0.95 (0.92-0.98)
 1 .008 3.8 (1.4-10.4)
 1 .011 6.3 (1.5-25.7)
 1 .182 0.37
 interval, CI.
128.383), Cox & Snell R2 (0.131).
d (120.058), Cox & Snell R2 (0.196).
A.L. Conroy et al. / International Journal of Infectious Diseases 40 (2015) 45–53 51Dengue has signiﬁcant health, economic and social impacts on
affected communities.81 On average, a hospitalized case of dengue
fever costs three times that of an ambulatory case,82 and tools that
can facilitate better patient triage at time of presentation with
fever may reduce unnecessary hospital admissions and support the
rational allocation of resources. A number of clinical signs and
symptoms, laboratory parameters and biochemical markers have
been associated with increased risk of clinical deterioration in
dengue infection. However, the predictive accuracy of individual
parameters varies according to the population studied and
epidemiologic risk factors, and viral genotype. Host genetics
may also affect host susceptibility to severe disease. The majority
of published papers focus on paediatric populations from
Southeast Asia; less is known about disease progression and
markers of disease severity in adult populations and populations
from Latin America. As Colombia has one of the highest rates of
severe dengue and associated mortality in the western hemi-
sphere24,83, it is important to identify markers that can facilitate
improved patient triage in this setting. In our study we found that
patient age and the presence of cutaneous hyperesthesia/
hyperalgesia, an under-recognized clinical symptom, were inde-
pendently associated with progression to DHF/DSS.
Of interest, two candidate biomarkers associated with DHF/DSS
progression in this study (CXCL10 and sICAM-1), are associated
with disease severity in other viral haemorrhagic fevers. Increases
in serum sICAM-1 and CXCL10 are associated with Crimean-Congo
haemorrhagic fever (CCHF), and haemorrhagic fever with renal
syndrome,84–87 and sICAM-1 has been identiﬁed as a predictive
marker of CCHF mortality.84 Serum CXCL10 has been found to be
signiﬁcantly higher in patients with fatal yellow fever and fatal
Zaire virus-associated Ebola virus disease (EVD); however, the
prognostic value was not assessed in these studies.88,89 Increases in
sICAM-1 have been associated with fatal outcomes in Ugandan
children with Sudan virus-associated EVD infection.90 In the same
outbreak, both sICAM-1 and CXCL10 were elevated in patients with
haemorrhage.91 These data suggest that the biomarker candidates
identiﬁed in our cohort may also identify patients at risk of
complications in other viral infections associated with endothelial
pathobiology and haemorrhage.
This study represents one of the larger studies to assess the
association of biomarkers with disease progression in samples
prospectively collected during acute disease. Although the results
are encouraging, they require validation in a larger prospective
study and longitudinal sampling over the course of illness to
evaluate biomarker kinetics. These ﬁndings also need to be
validated using the new WHO dengue classiﬁcation system to
determine how the biomarkers relate to warning signs, organ
dysfunction, and the development of severe dengue. Although
further mechanistic studies are required to elucidate the role, if
any, of the markers on mediating disease, our ﬁndings suggest
there may be speciﬁc immune signatures that precede clinical
deterioration. Further investigations into these pathways may
identify novel markers to assist in patient triage, and inform the
design of new interventions.
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